Repligen Corporation (NASDAQ:RGEN) Shares Purchased by KBC Group NV

KBC Group NV boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 14.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 2,544 shares of the biotechnology company’s stock after acquiring an additional 329 shares during the period. KBC Group NV’s holdings in Repligen were worth $324,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC raised its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen in the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. purchased a new position in Repligen in the 4th quarter worth approximately $40,000. Finally, Center for Financial Planning Inc. boosted its holdings in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 193 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of a number of recent research reports. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $172.83.

Repligen Stock Up 0.3%

Repligen stock opened at $127.36 on Friday. The company has a market capitalization of $7.16 billion, a PE ratio of -283.02, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The firm has a 50 day moving average price of $126.70 and a 200 day moving average price of $139.91.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. Research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.